Recently, two new antiemetics, aprepitant, the first member of the neurokinin-1 antagonists, and palonosetron, a second-generation 5-hydroxytryptamine receptor antagonist, received regulatory ...

Nat Clin Pract Oncol. 2005;2(4):196-201. In all three studies, antiemetic treatment was well tolerated with no significant differences in the frequency of adverse events between the three arms.